[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:11][C:12]2[C:13]3[N:29]=[CH:28][S:27][C:14]=3[N:15]=[C:16]([N:18]3[CH2:23][CH2:22][CH:21]([C:24]([OH:26])=O)[CH2:20][CH2:19]3)[N:17]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10].Br.[NH2:31][CH2:32][CH2:33][C:34]1[CH:39]=[CH:38][NH:37][C:36](=[O:40])[CH:35]=1.C(Cl)CCl.CN1C=CN=C1>C(Cl)Cl>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:11][C:12]2[C:13]3[N:29]=[CH:28][S:27][C:14]=3[N:15]=[C:16]([N:18]3[CH2:19][CH2:20][CH:21]([C:24]([NH:31][CH2:32][CH2:33][C:34]4[CH:39]=[CH:38][NH:37][C:36](=[O:40])[CH:35]=4)=[O:26])[CH2:22][CH2:23]3)[N:17]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10]The mixture of 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)piperidine-4-carboxylic acid (70 mg, 0.22 mmol), 4-(2-aminoethyl)pyridin-2(1H)-one hydrobromide (70 mg, 0.32 mmol), EDC (170 mg, 0.89 mmol) and 1-methyl-1H-imidazole (108 mg, 1.32 mmol) in 20 mL of DCM was stirred at room temperature overnight. Excess of DCM was removed under reduced pressure and the residue was triturated with H2O (30 mL) and EtOAc (20 mL) then dried under reduce pressure to give 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(2-(2-oxo-1,2-dihydropyridin-4-yl)ethyl)piperidine-4-carboxamide (25 mg, 40%) as a yellow solid. 1H NMR (300 MHz, CD3OD): δ 8.62 (s, 1H), 7.61 (d, 1H, J=2.4 Hz), 7.35 (d, 1H, J=7.2 Hz), 7.20 (dd, 1H, J1=8.7 Hz, J2=2.4 Hz), 6.95 (d, 1H, J=8.7 Hz), 6.36-6.32 (m, 2H), 4.83-4.79 (m, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.44 (t, 2H, J=6.8 Hz), 3.00-2.92 (m, 2H), 2.70 (t, 2H, J=6.8 Hz), 2.45 (brs, 1H), 1.80-1.64 (m, 4H). LC-MS: 536 [M+H]+, 534 [M−H]−, tR=1.38 min. HPLC: 95.70% at 214 nm, 96.10% at 254 nm, tR=3.65 min.
読み込み中…